In the field of oncology research, PT109, a novel multikinase inhibitor, reprogrammes glioblastoma multiforme (GBM) into oligodendrocytes by decreasing the level of PTBP1 and increasing the ratio of pyruvate kinase M1/2 (PKM1/2), and alters the metabolic pattern of GBM via the PTBP1/PKM1/2 pathway [49]. This evidence concerns the gene PTBP1 and glioblastoma.